Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical tria... by Carsten Flohr, Michael J. Cork, Michael R. Ardern-Jones, Lawrence F. Eichenfield, Sébastien Barbarot, Claire Feeney, Ricardo Rojo, Irina Lazariciu, John Nesnas

Connect to this object online.

Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc a... by Melinda J. Gooderham, Michael R. Ardern‐Jones, Emma Guttman‐Yassky, Mahreen Ameen, Eric L. Simpson, Gary Chan, Pinaki Biswas, Wing S. Chiu, Melissa Watkins

Connect to this object online.

Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin typesCapsule Summary by Angela L. Bosma, MD, Wouter Ouwerkerk, PhD, Madeline J. Heidema, MD, David Prieto-Merino, PhD, Michael R. Ardern-Jones, MD, PhD, Paula Beattie, MD, Sara J. Brown, MD, PhD, John R. Ingram, MD, PhD, Alan D. Irvine, MD, DSc, Graham Ogg, MD, PhD, Prakash Patel, BSc, Nick J. Reynolds, MD, PhD, R.M. Ross Hearn, MD, Mandy Wan, PhD, Richard B. Warren, MD, PhD, Richard T. Woolf, MD, PhD, Ariënna M. Hyseni, Louise A.A. Gerbens, MD, PhD, Phyllis I. Spuls, MD, PhD, Carsten Flohr, MD, PhD, Maritza A. Middelkamp-Hup, MD, PhD

Connect to this object online.